echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > "Pharmaceutical headlineking" US government buys Gilead Redsewey supply for the next three months.

    "Pharmaceutical headlineking" US government buys Gilead Redsewey supply for the next three months.

    • Last Update: 2020-07-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    (2020/07/02) From July 1st, a large number of drug health insurance will no longer be reimbursed; the life and death fatigue of confirmed takeaways and 6 million riders: the virus is terrible but more urgent to make money; and the 500 billion-dollar Hengrui has been working on innovative projects in the last 10 yearsForeign media pharmaphorum.com recently reported that the U.Sgovernment has reached a procurement agreement with Gilead Science to buy out almost all of Redsewe's supply over the next three monthsThis means that for at least the next three months, the UK, the EU and other countries will not be able to buy Ridsewe, or face the embarrassment of being almost "drug-free"this is a very great" agreementrecently many medical insurance bureau intensive text, according to Thesaiblue incomplete statistics, Yunnan, Hunan, Jilin, Tianjin, Hebei, Anhui, Tibet and other places have been clear the first batch of transfer out of the local medical insurance supplementary varieties, a large number of varieties from the 1st out of the local medical insurance directorythe digestion of local health insurance supplements will continueOn June 23,, one of the confirmed cases of the Beijing outbreak included a 47-year-old rider, MrKong, who heard the news, and Li Liang's brain-neutral horse emerged with a picture: a 50-year-old new crown patient, desperately trying to breathe before he died, struggling for a minute with a drowning man's generally strong desire to survive, until he diedriders have work to work in a way that many other types of work cannot be comparedthe trend of global integration, more and more pharmaceutical companies through the "license-in" and "license-out" model, improve pipeline layout, improve the efficiency of research and developmentAs a star of China's pharmaceutical industry, Hengrui also used this model to steadily promote its "going out" and "introduce" strategy, let's review Hengrui's foreign trade cooperation over the past 10 yearsHengrui Pharmaceuticals continues to upgrade its competitivenessthe 2015 drug review reform, China's pharmaceutical industry began to change from "sales-driven" to "research and development-driven"Consistency evaluation in coordination with the "4 plus 7" and other series of supporting policies to promote generic drug market shuffling, in this context, the pharmaceutical companies have greatly increased investment in research and development, in addition to investing a lot of money for the research and development of class 1 new drug, the first imitation is the major pharmaceutical companies to develop generic drugs the best strategythe technical barriers of the first generic drug are high and have a first-mover advantage, the extraordinary 2020 is half way throughFrom the perspective of the global secondary market, there has been a period of "brutal" in the past six months: four fuses in 10 days and a collapse in the US share marketIt was March 2020, in the shadow of the then repeated "crash", and it seemed that as long as it did not melt, it was good newsbiopharmaceutical sector is indeed growing stronglya few days ago, quvovoprosineye drops face the first review, sodium glass acid drop eye drops meet the third reviewMinne net data show that the current 6 eye drops have been evaluated by enterprises, of which 4 are among the 2019 China public medical institutions terminal eye drops TOP15;left oxyfluorosaosa eye drops have been proposed for inclusion in the third batch of national harvesting.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.